HPV-16 E6 and E7 oncogene expression is downregulated as a result of Mdm2 knockdown

International Journal of Oncology

Volumn 41, Issue 1, 2012, Pages 141-146

  Diaz, Daniel ^a   Salinas Santander, Mauricio A ^b   Morlett Chavez, Jesús A ^a  

^a UNIVERSIDAD AUTÓNOMA DE COAHUILA   (Mexico)

^b UNIVERSIDAD AUTÓNOMA DE NUEVO LEÓN   (Mexico)

Author keywords

Cervical cancer; E6; E7; HPV 16; Mdm2; RNAi

Indexed keywords

GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MESSENGER RNA; PROTEIN E6; PROTEIN E7; PROTEIN MDM2; PROTEIN P53; RETINOBLASTOMA PROTEIN;

ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; CONTROLLED STUDY; DOWN REGULATION; E6 ONCOGENE; E7 ONCOGENE; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; NEGATIVE FEEDBACK; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; UPREGULATION; VIRUS CELL INTERACTION;

CELL LINE, TUMOR; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HOST-PATHOGEN INTERACTIONS; HUMAN PAPILLOMAVIRUS 16; HUMANS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS INFECTIONS; PROTO-ONCOGENE PROTEINS C-MDM2; REPRESSOR PROTEINS; RNA INTERFERENCE; TUMOR SUPPRESSOR PROTEIN P53; UTERINE CERVICAL NEOPLASMS;

EID: 84862885986     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1429     Document Type: Article

References (36)

1. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, et al: Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J Natl Cancer Inst 87: 796-802, 1995.
2. Münger K and Howley PM: Human papillomavirus immortalization and transformation functions. Virus Res 89: 213-228, 2002. (Pubitemid 35351540)
3. Greenblatt RJ: Human papillomaviruses: diseases, diagnosis, and a possible vaccine. Clin Microbiol Newslett 27: 139-145, 2005.
4. Sinal SH and Woods CR: Human papillomavirus infections of the genital and respiratory tracts in young children. Semin Pediatr Infect Dis 16: 306-316, 2005. (Pubitemid 41422334)
5. Noel JC, Lespagnard L, Fayt I, Verhest A and Dargent JL: Evidence of human papilloma virus infection but lack of Epstein-Barr virus in lymphoepithelioma-like carcinoma of uterine cervix: report of two cases and review of the literature. Hum Pathol 32: 135-138, 2001. (Pubitemid 32150642)
6. Baseman JG and Koutsky LA: The epidemiology of human papillomavirus infections. J Clin Virol 32: 16-24, 2005.
7. Goodwin EC and DiMaio D: Repression of human papillomavirus oncogenes in HeLa cervical carcinoma cells causes the orderly reactivation of dormant tumor suppressor pathways. Proc Nat Acad Sci USA 97: 12513-12518, 2000.
8. Kubbutat MH and Vousden KH: New HPV E6 binding proteins: dangerous liaisons? Trends Microbiol 6: 173-175, 1998. (Pubitemid 28259581)
9. Rapp L and Chen JJ: The papillomavirus E6 proteins. Biochim Biophys Acta 1378: F1-F19, 1998. (Pubitemid 28381124)
10. Park DJ, Wilczynski SP, Paquette RL, Miller CW and Koeffler HP: p53 mutations in HPV-negative cervical carcinoma. Oncogene 9: 205-210, 1994.
11. Denk C, Butz K, Schneider A, Dürst M and Hoppe-Seyler F: p53 mutations are rare events in recurrent cervical cancer. J Mol Med 79: 283-288, 2001. (Pubitemid 32646384)
12. Zehbe I, Voglino G, Wilander E, Delius H, Marongiu A, Edler L, et al: p53 codon 72 polymorphism and various human papillomavirus 16 E6 genotypes are risk factors for cervical cancer development. Cancer Res 61: 608-611, 2001. (Pubitemid 32128622)
13. Butz K, Whitaker N, Denk C, Ullmann A, Geisen C and Hoppe-Seyler F: Induction of the p53-target gene GADD45 in HPV-positive cancer cells. Oncogene 18: 2381-2386, 1999. (Pubitemid 29192716)
14. Von Knebel Doeberitz M, Rittmuller C, zur Hausen H and Durst M: Inhibition of tumorigenicity of cervical cancer cells in nude mice by HPV E6-E7 anti-sense RNA. Int J Cancer 51: 831-834, 1992.
15. Hietanen S, Lain S, Krausz E, Blattner C and Lane DP: Activation of p53 in cervical carcinoma cells by small molecules. Proc Natl Acad Sci USA 97: 8501-8506, 2000. (Pubitemid 30639702)
16. Momand J, Zambetti GP, Olson DC, George D and Levine AJ: The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69: 1237-1245, 1992.
17. Finlay CA: The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth. Mol Cell Biol 13: 301-306, 1993.
18. Chen J, Wu X, Lin J and Levin AJ: mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein. Mol Cell Biol 16: 2445-2452, 1996. (Pubitemid 26123766)
19. Haupt Y, Barak Y and Oren M: Cell type-specific inhibition of p53-mediated apoptosis by mdm2. EMBO J 15: 1596-1606, 1996. (Pubitemid 26112381)
20. Hengstermann A, Linares LK, Ciechanover A, Whitaker NJ and Scheffner M: Complete switch from Mdm2 to human papillomavirus E6-mediated degradation of p53 in cervical cancer cells. Proc Natl Acad Sci USA 98: 1218-1223, 2001. (Pubitemid 32121213)
21. Gammoh N, Gardiol D, Massimi P and Banks L: The Mdm2 ubiquitin ligase enhances transcriptional activity of human papillomavirus E2. J Virol 83: 1538-1543, 2009.
22. Hall AH and Alexander KA: RNA interference of human papillomavirus type 18 E6 and E7 induces senescence in HeLa cells. J Virol 77: 6066-6069, 2003. (Pubitemid 36538997)
23. Gu W, Putral L, Hengst K, Minto K, Saunders NA, Leggatt G, et al: Inhibition of cervical cancer cell growth in vitro and in vivo with lentiviral-vector delivered short hairpin RNA targeting human papillomavirus E6 and E7 oncogenes. Cancer Gene Ther 13: 1023-1032, 2006. (Pubitemid 44564738)
24. Koivusalo R, Mialon A, Pitkänen H, Westermarck J and Hietanen S: Activation of p53 in cervical cancer cells by human papillomavirus E6 RNA interference is transient, but can be sustained by inhibiting endogenous nuclear export-dependent p53 antagonists. Cancer Res 66: 11817-11824, 2006. (Pubitemid 46094193)
25. Vogt M, Butz K, Dymalla S, Semzow J and Hoppe-Seyler F: Inhibition of Bax activity is crucial for the antiapoptotic function of the human papillomavirus E6 oncoprotein. Oncogene 25: 4009-4015, 2006. (Pubitemid 44024863)
26. Cheng YW, Wu MF, Wang J, Yeh KT, Goan YG, Chiou HL, et al: Human papillomavirus 16/18 E6 oncoprotein is expressed in lung cancer and related with p53 inactivation. Cancer Res 67: 10686-10693, 2007. (Pubitemid 350145894)
27. Khvorova A, Reynolds A and Jayasena SD: Functional siRNAs and miRNAs exhibit strand bias. Cell 115: 209-216, 2003. (Pubitemid 37329584)
28. Reynolds A, Leake D, Boese Q, Scaringe S, Marshall WS and Khvorova A: Rational siRNA design for RNA interference. Nat Biotechnol 22: 326-330, 2004. (Pubitemid 38295766)
29. Ui-Tei K, Naito Y, Takahashi F, Haraguchi T, Ohki-Hamazaki H, Juni A, et al: Guidelines for the selection of highly effective siRNA sequences for mammalian and chick RNA interference. Nucleic Acids Res 32: 936-948, 2004. (Pubitemid 38854696)
30. Traidej M, Chen L, Yu D, Agrawal S and Chen J: The roles of E6-AP and MDM2 in p53 regulation in human papillomavirus-positive cervical cancer cells. Antisense Nucleic Acid Drug Dev 10: 17-27, 2000. (Pubitemid 30148186)
31. Boyer SN, Wazer DE and Band V: E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res 56: 4620-4624, 1996. (Pubitemid 26338060)
32. Gonzalez SL, Stremlau M, He X, Basile JR and Münger K: Degradation of the retinoblastoma tumor suppressor by the human papillomavirus type 16 E7 oncoprotein is important for functional inactivation and is separable from proteasomal degradation of E7. J Virol 75: 7583-7591, 2001. (Pubitemid 32738016)
33. Koivusalo R, Krausz E, Helenius H and Hietanen S: Chemotherapy compounds in cervical cancer cells primed by reconstitution of p53 function after short interfering RNA-mediated degradation of human papillomavirus 18 E6 mRNA: opposite effect of siRNA in combination with different drugs. Mol Pharmacol 68: 372-382, 2005. (Pubitemid 41058301)
34. Ham J, Dostatni N, Gauthier JM and Yaniv M: The papillomavirus E2 protein: a factor with many talents. Trends Biochem Sci 16: 440-444, 1991. (Pubitemid 121004490)
35. Del Vecchio AM, Romanczuk H, Howley PM and Baker CM: Transient replication of human papillomavirus DNAs. J Virol 66: 5949-5958, 1992.
36. Demeret C, Desaintes C, Yaniv M and Thierry F: Different mechanisms contribute to the E2-mediated transcriptional repression of human papillomavirus type 18 viral oncogenes. J Virol 71: 9343-9349, 1997. (Pubitemid 27492376)